Navigation Links
Trial success for diabetic nerve therapy

A potentially ground-breaking treatment for nerve damage caused by diabetes has shown promising results in preclinical and early patient trials.

The University of Manchester team has discovered that injection of a novel therapeutic that works by stimulating a person's genes may prevent nerve damage ?primarily to the hands and feet ?caused by the disease.

The positive preclinical results ?reported in the journal Diabetes ?are further evidence that the research could lead to a new treatment for diabetic nerve damage or 'neuropathy'; initial-stage clinical trials on patients in the United States have also been encouraging.

Lead researcher Professor David Tomlinson says the study has massive potential for managing the condition and preventing thousands of foot amputations each year.

"The vast majority of non-traumatic hand and foot amputations carried out in UK hospitals are caused by diabetes and there are currently no treatments available to prevent or slow the progress of nerve disease in diabetic patients," he said.

"Our tests have shown that a single injection of a DNA-binding protein protected nerve function, stimulated nerve growth and prevented tissue damage that in humans can lead to limb loss."

An estimated 50 per cent of patients with long-term diabetes develop some form of neuropathy that can cause numbness and sometimes pain and weakness in the hands, arms, feet and legs. Progression to amputation is not inevitable, but it is always a threat.

Problems may also occur in other organs, including the heart, kidneys, sex organs, eyes and digestive tract.

"Diabetic neuropathy is a major problem in insulin-dependent diabetes, particularly in patients who have had the disease for a period of time," said Professor Tomlinson, who is based in the University's Faculty of Life Sciences.

"Our approach to gene therapy is quite different to previous attempts at treatment: we use a DNA-binding protein c
'"/>

Source:University of Manchester


Page: 1 2

Related biology news :

1. FDA Approves Human Hookworm Vaccine for Phase I Safety Trials
2. NIAID Initiates Trial of Experimental Avian Flu Vaccine
3. Bird Brains Show How Trial and Error May Contribute to Learning
4. EuroVacc 02 HIV Vaccine Trial Begins
5. Visceral Leishmaniasis: Successful Vaccine Trial In Dogs
6. Trials for new drug to overcome HIV
7. New, automated tool successfully classifies and relates proteins in unprecedented way
8. Biomarkers isolated from saliva successfully predict oral and breast cancer
9. Secret of smallpoxs success may lead to bioterror cure
10. UN successfully tests green pesticide against locusts
11. Stem cell therapy successfully treats heart attack in animals
Post Your Comments:
*Name:
*Comment:
*Email:
TAG: Trial success for diabetic nerve therapy

(Date:9/18/2014)... algal forests in the eastern Mediterranean Sea pose a ... distribution continues to expand as the climate warms, a ... of researchers led by Dr Adriana Vergs of UNSW ... for Advanced Studies in Spain, is published in the ... surveyed more than 1000 kilometres of coastline in Turkey ...
(Date:9/18/2014)... the ideal animal in which to study the genes ... into tens of thousands of freshwater streams and lakes ... adapt to the new environment. , Breeding studies between ... up one of the genes that controls tooth number, ... regulation in a freshwater population is associated with a ...
(Date:9/17/2014)... accessible and affordable health care to reproductive technologies, ... on the ability of people to identify key ... and respectfully, and find the most defensible ways ... to support these societal conversations?, The Hastings Center ... Bioethical Issues have teamed up to publish a ...
Breaking Biology News(10 mins):Tropical fish a threat to Mediterranean Sea ecosystems 2Counting fish teeth reveals regulatory DNA changes behind rapid evolution, adaptation 2Counting fish teeth reveals regulatory DNA changes behind rapid evolution, adaptation 3Why bioethics literacy matters 2Why bioethics literacy matters 3
... a huge portion of real estate in western North ... and fossils very different from those in adjacent terranes. ... tectonic styles, metamorphism, and volcanic origins, much like the ... new Geological Society of America Special Paper brings together ...
... Washington, DCMay 28, 2008The 2008 American Society for ... Diagnostic Immunology is presented to Steven A. Rosenberg, ... Surgery, Uniformed Services University of the Health Sciences, ... of Medicine and Health Sciences. Sponsored by Abbott ...
... for Microbiology (ASM) Merck Irving S. Sigal Memorial Award ... Genetics and Microbiology, University of Texas at Austin. Sponsored ... Memorial Award is presented in memory of Irving S. ... therapies to treat HIV/AIDS, to recognize excellence in basic ...
Cached Biology News:American Society for Microbiology honors Steven A. Rosenberg 2
(Date:9/19/2014)... Jose, California (PRWEB) September 19, 2014 ... Nanotechnology and its potential to revolutionize the world ... agencies, multinational corporations and small start-ups. The early ... funded research projects largely due to the high ... investments. Government budgets earmarked for this evolving technology ...
(Date:9/19/2014)... , Sept. 19, 2014 Pfenex Inc. ... the development of high-value and difficult to manufacture proteins ... presenting at the 21 st Annual NewsMakers in ... . Bertrand Liang , chief executive officer ... development programs and business strategy on Friday, September 26, ...
(Date:9/19/2014)... 19, 2014 ... ) has announced the addition of the  "Micro ... to their offering.       (Logo: http://photos.prnewswire.com/prnh/20130307/600769) ... of the fastest-growing segments in the chromatography market. ... 2013, and expected to reach $2.0 billion by ...
(Date:9/18/2014)... September 18, 2014 HealthTronics, ... and interventional radiology products and services, announced that ... cryotherapy and cryoablation) versus external beam radiotherapy (EBRT) ... the American Urological Association (MAAUA) Annual Meeting in ... Relative Effectiveness of Cryosurgery and External Beam Radiation ...
Breaking Biology Technology:Growing R&D Investments & Developments in Nanomaterials to Drive the Global Nanotechnology Market, According to New Report by Global Industry Analysts, Inc. 2Growing R&D Investments & Developments in Nanomaterials to Drive the Global Nanotechnology Market, According to New Report by Global Industry Analysts, Inc. 3Growing R&D Investments & Developments in Nanomaterials to Drive the Global Nanotechnology Market, According to New Report by Global Industry Analysts, Inc. 4Pfenex to Present at Upcoming Industry Conference on September 26 2Micro Market Monitor : Global Pre-packed Chromatography Columns 2HealthTronics Announces Data Comparing Cryotherapy Versus Radiation for Treating Prostate Cancer Poster Presented at the American Urological Association Regional Meeting 2
... ATLANTA, Oct. 12, 2011 CorMatrix Cardiovascular, Inc., ... delivering unique extracellular matrix (ECM) biomaterial devices that ... cardio-vascular tissue, announced today that the U.S. Food ... 510(k) clearance to market its CorMatrix® ECM® for ...
... 2011 Reportlinker.com announces that a new ... catalogue: Industrial Biotechnology ... http://www.reportlinker.com/p0655292/Industrial-Biotechnology-China-News-1109---Annual-Subscription.html#utm_source=prnewswire&utm_medium=pr&utm_campaign=Renewable_energy ... of Biotechnology Industry to be published in ...
... - Two pivotal trials initiated for treatment of iron ... - Shield Therapeutics (Shield), the independent specialty ... late-stage, mineral-derived hospital pharmaceuticals which address areas of high ... have been treated in the two Phase 3 clinical ...
Cached Biology Technology:CorMatrix Receives Carotid Artery Repair Indication for its CorMatrix® ECM® 2CorMatrix Receives Carotid Artery Repair Indication for its CorMatrix® ECM® 3Industrial Biotechnology China News 1109 - Annual Subscription 2Industrial Biotechnology China News 1109 - Annual Subscription 3Shield Therapeutics Initiates AEGIS 1 and AEGIS 2 Phase 3 Studies of ST10 2Shield Therapeutics Initiates AEGIS 1 and AEGIS 2 Phase 3 Studies of ST10 3
... is a new-generation siRNA transfection reagent that ... 1 nM siRNA in a wide variety ... cell viability. Using low siRNA concentrations avoids ... when transfecting siRNA at higher concentrations, thereby ...
... Cell and Tissue Staining Kits are intended ... range of histological and cytological specimens. These ... antibodies manufactured by either R&D Systems or ... on the formation of the Avidin-Biotin Complex ...
... stranded RNA (dsRNA) has been shown to ... of organisms as well as insect cells ... inhibition of protein expression by utilizing sequence-specific, ... (mRNA). Attempts to induce RNA interference using ...
... jetSI-ENDO is an easy-to-use siRNA transfection reagent ... endogenous genes in a variety of cell ... with an optimized, straightforward protocol. High levels ... obtained following transfection of 20 to 100 ...
Biology Products: